Low-Molecular-Weight Heparins in the Cardiac Catheterization Laboratory

Texas Heart Institute Journal

Volumn 31, Issue 1, 2004, Pages 72-83

  Kadakia, Rajan A ^a,b   Baimeedi, Shravantika R ^a   Ferguson, James J ^a,b,c  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Angioplasty, transluminal, percutaneous coronary; Anticoagulants; Antithrombin therapy; Myocardial revascularization; Platelet glycoprotein GP IIb IIIa complex antagonists inhibitors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CERTOPARIN; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FISH OIL; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RETEPLASE; REVIPARIN; STREPTOKINASE; TENECTEPLASE; TICLOPIDINE;

BLEEDING; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG MECHANISM; HEART CATHETERIZATION; HEART MUSCLE REVASCULARIZATION; HEMATURIA; HUMAN; LABORATORY; OCCULT BLOOD; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PHYSICIAN; REVIEW; SIDE EFFECT; THROMBOSIS; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; HEART CATHETERIZATION; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LABORATORIES, HOSPITAL; RANDOMIZED CONTROLLED TRIALS;

EID: 1642274591     PISSN: 07302347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593-601.
2. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337(7):447-52.
3. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, Braunwald E. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100(15):1602-8.
4. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436-43.
5. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators [published erratum appears in N Engl J Med 1998;339:4151]. N Engl J Med 1998;338:1488-97.
6. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators [published erratum appears in N Engl J Med 1998;339:4151]. N Engl J Med 1998;338:1488-97.
7. Cohen M, Theroux P, Borzak S, Frey MJ, White HD, Van Mieghem W, et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. Am Heart J 2002;144(3):470-7.
8. Weitz JI. Low-molecular-weight heparins [published erratum appears in N Engl J Med 1997;337:1567]. N Engl J Med 1997;337(10):688-98.
9. Weitz JI. Low-molecular-weight heparins [published erratum appears in N Engl J Med 1997;337:1567]. N Engl J Med 1997;337(10):688-98.
10. Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994;71(3):300-4.
11. Faxon DP, Spiro TE, Minor S, Cote G, Douglas J, Gottlieb R, et al. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. Circulation 1994;90(2):908-14.
12. Cairns JA, Gill J, Morton B, Roberts R, Gent M, Hirsh J, et al. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study. Circulation 1996; 94(7):1553-60.
13. Grassman ED, Leya F, Fareed J, Lewis BE, Bacher P, Loeb HS, Moran JF. A randomized trial of the low-molecular-weight heparin certoparin to prevent restenosis following coronary angioplasty. J Invasive Cardiol 2001;13(11):723-8.
14. Zidar JP. Low-molecular-weight heparins in coronary stenting (the ENTICES trial). ENoxaparin and TIClopidine after Elective Stenting. Am J Cardiol 1998;82(5B):29L-32L.
15. Batchelor WB, Mahaffey KW, Berger PB, Deutsch E, Meier S, Hasselblad V, et al. A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial. J Am Coll Cardiol 2001;38(6):1608-13.
16. Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, et al. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation. J Am Coll Cardiol 1996;28(6):1437-43.
17. Rabah MM, Premmereur J, Graham M, Fareed J, Hoppensteadt DA, Grines LL, Grines CL. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84:1391-5.
18. Martin JL, Fry ET, Sanderink GJ, Atherley TH, Guimart CM, Chevalier PJ, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv 2004;61:163-70.
19. Kereiakes DJ, Kleiman NS, Fry E, Mwawasi G, Lengerich R, Maresh K, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001;141:348-52.
20. Choussat R, Montalescot G, Collet JP, Vicaut E, Ankri A, Gallois V, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002;40:1943-50.
21. Kereiakes DJ, Grines C, Fry E, Esente P, Hoppensteadt D, Midei M, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001;13(4):272-8.
22. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/ IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.
23. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336: 1689-96.
24. Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol 2003;41(1):20-5.
25. Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-63.
26. Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA, et al. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE 3) study. Am Heart J 2003;146:628-34.
27. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330: 956-61.
28. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
29. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997;96:1445-53.
30. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A; Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107(2):238-44.
31. Moliterno DJ, Hermiller JB, Kereiakes DJ, Yow E, Applegate RJ, Braden GA, et al. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. J Am Coll Cardiol 2003;42(6):1132-9.
32. Henry TD, Satran D, Knox LL, Iacarella CL, Laxson DD, Antman EM. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin? Am Heart J 2001;142(4):590-3.
33. Schooley CC, Gilbert JH, Harlan M, Bracey A, Coulter S, Wilson JM. Kinetics of intravenously administered dalteparin [abstract]. J Am Coll Cardiol 2003;41(6 Suppl A): 25A.
34. Marmur JD, Anand SX, Bagga RS, Fareed J, Pan CM, Sharma SK, Richard MF. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol 2003;41(3):394-402.
35. Lawrence M, Mixon T, Cross D, Dehmer G. Assessment of anticoagulation using activated clotting times in patients receiving intravenous enoxaparin during percutaneous coronary intervention [abstract]. J Am Coll Cardiol 2003;41 (6 Suppl A):68A.
36. Keriakes DJ, Montalescot G, Antman EM, Cohen M, Darius H, Ferguson JJ, et al. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. Am Heart J 2002;144(4):615-24.
37. Kadakia RA, Ferguson JJ. Use of enoxaparin in patients undergoing percutaneous coronary intervention. Critical Pathways in Cardiology 2003;2(1):1-6.
38. Antman EM, Louwerenburg HW, Baars HF, Wesdorp JC, Hamer B, Bassand JP, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial [published erratum appears in Circulation 2002;105:2799]. Circulation 2002;105:1642-9.
39. Antman EM, Louwerenburg HW, Baars HF, Wesdorp JC, Hamer B, Bassand JP, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial [published erratum appears in Circulation 2002;105:2799]. Circulation 2002;105:1642-9.
40. Dubois CL, Belmans, Granger CB, Armstrong PW, Wallentin L, Fioretti PM, et al. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. J Am Coll Cardiol 2003;42:1178-85.
41. Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 2002;360(9335): 743-51.
42. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol 1998;82(5B):3L-10L.
43. Michalis LK, Katsouras CS, Papamichael N, Adamides K, Naka KK, Goudevenos J, Sideris DA. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Am Heart J 2003; 146(2):304-10.
44. SYNERGY Executive Committee. Superior Yield of the New strategy of Enoxaparin, Revascularization and GlYco-protein IIb/IIIa inhibitors. The SYNERGY trial: study design and rationale. Am Heart J 2002;143(6):952-60.
45. Wong G, Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA 2003;289(3):331-42.